Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883272 · ClinicalTrials.gov registry record
Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 32
- Enrollment target
NCT00883272: Completed study, sponsored by NYU Langone Health.
NCT00883272 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00883272 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Femeralle (DT56a) has an effect on the coagulation system, measured by platelet adhesion and aggregation, of normal and thrombophilic postmenopausal women.
Interventions
- DIETARY_SUPPLEMENT DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
What the finished NCT00883272 record still lists
NCT00883272 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel] is the first listed.
NCT00883272 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00883272 about?
NCT00883272 is a clinical study titled "Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women". The purpose of this study is to determine if Femeralle (DT56a) has an effect on the coagulation system, measured by platelet adhesion and aggregation, of normal and thrombophilic postmenopausal women.
What is the current status of trial NCT00883272?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2007-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00883272?
The interventions under investigation include: DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel] (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00883272?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia